View:
Download DOC
Download PDF
Download XLS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: July 12, 2023

 

Commission File Number: 001-38844

 

GENFIT S.A.

(Translation of registrant’s name into English)

 

Parc Eurasanté

885, avenue Eugène Avinée

59120 Loos, France

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F          ☐ Form 40-F

  

 

 

EXHIBIT LIST

     

Exhibit

  

Description

   
99.1   Press Release dated July 12, 2023.
   
     
   
     

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

             
        GENFIT S.A.
       
Date: July 12, 2023       By:   /s/ Pascal PRIGENT
            Name: Pascal PRIGENT
            Title: Chief Executive Officer

 

Exhibit 99.1

 

 

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

 

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 12, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

 

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2023:

 

·123,140 shares
·€616 333.35

 

During the first half of 2023, total trading was:

 

·On the buy side: 962,200 shares for a total amount of €3,686,246.47
 ·On the sell side: 977,751 shares for a total amount of €3,768,509.64

 

During this same period, the number of trades were:

 

·On the buy side: 2,143
·On the sell side: 1,854

 

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

 

·27, 911 shares
·€769 849,43

 

 

ABOUT GENFIT

 

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development. A successful Phase III trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC) is the fruit of a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a

 

1

growing and diversified pipeline of innovative therapeutic and diagnostic solutions. Its R&D pipeline covers six therapeutic areas via seven programs which explore the potential of differentiated mechanisms of action, across a variety of development stages (pre-clinical, Phase 1, Phase 2, Phase 3). These diseases are acute on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD), organic acidemias (OA) and PBC. Beyond therapeutics, GENFIT’s pipeline also includes a diagnostic franchise focused on NASH and ACLF. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. For more information, visit www.genfit.com

 

FORWARD LOOKING STATEMENTS

 

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995 in relation to GENFIT’s research and development programs. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “targeted”, “anticipated”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, cost of, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, potential synergies related to the acquisition of Versantis, our capacity to integrate its assets, develop its programs and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2022 Universal Registration Document filed with the Autorité des marches financiers (AMF) on April 18, 2023, which is available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023. In addition, even if the

 

2

Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

 

CONTACT

 

GENFIT | Investors

 

Tel: +33 3 2016 4000 | investors@genfit.com

 

PRESS RELATIONS | Media

 

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

 

3

 

APPENDIX H1

2023

 

  Buy side Sell side

 

Date

 

Number of

executions

 

Number of

shares

 

Traded amounts in

EUR

 

Number of executions

 

Number

of shares

 

 

Traded amounts in

EUR

TOTAL 2 143 962 200 3 686 246,47 1 854 977 751 3 768 509,64

02/01/20

23

 19 7387 29 261,02 10 4688 18 705,12

03/01/20

23

 12 4448 17 418,06 8 3390 13 346,26

04/01/20

23

 23 11165 43 266,05 10 4665 18 237,54

05/01/20

23

 23 7744 29 456,94 9 3798 14 500,92

06/01/20

23

 7 3936 15 202,76 22 9718 37 479,31

09/01/20

23

 17 8751 33 823,58 11 6281 24 424,80

10/01/20

23

 23 8329 31 405,58 4 2961 11 114,29

11/01/20

23

 19 5803 21 860,02 8 4303 16 315,08

12/01/20

23

 27 7871 29 418,65 17 6793 25 577,28

13/01/20

23

 9 4144 15 383,27 5 2157 8 056,11

16/01/20

23

 10 5147 19 520,25 22 11490 43 423,12

17/01/20

23

 12 4494 16 983,50 18 6053 23 006,18

18/01/20

23

 8 2742 10 337,50 7 2742 10 392,32

19/01/20

23

 14 1844 6 952,60 7 2925 11 071,13

20/01/20

23

 8 3538 13 393,31 4 2457 9 356,26

23/01/20

23

 8 3806 14 398,29 11 3710 14 121,89

24/01/20

23

 16 3365 12 725,05 5 50781 190 472,42

25/01/20

23

 9 1001 3 783,75 4 1419 5 352,45

26/01/20

23

 11 5280 19 850,11 4 757 2 873,57

27/01/20

23

 2 37 140,19 10 6987 26 603,49

30/01/20

23

 17 8395 31 773,65 9 5383 20 381,92

31/01/20

23

 1 1 3,82 23 4758 18 328,29

 

 

4

01/02/20

23

 13 4068 15 838,64 8 2476 9 698,84

02/02/20

23

 16 2968 11 616,43 18 6642 26 146,90

03/02/20

23

 11 4161 16 960,69 22 12782 52 496,06

06/02/20

23

 14 6820 28 527,79 11 8516 35 926,79

07/02/20

23

 19 7631 32 341,86 9 4492 19 218,75

08/02/20

23

 15 4179 17 999,54 24 6948 29 939,28

09/02/20

23

 10 6439 27 631,87 18 8219 35 533,61

10/02/20

23

 29 12054 51 997,34 15 7779 33 640,29

13/02/20

23

 36 15965 67 548,07 11 3965 17 197,28

14/02/20

23

 10 5025 20 641,95 6 2342 9 681,43

15/02/20

23

 12 11460 46 191,94 23 10682 43 349,27

16/02/20

23

 13 5012 20 401,10 9 3346 13 684,97

17/02/20

23

 18 8712 35 319,75 14 5949 24 315,65

20/02/20

23

 11 4932 19 724,60 3 938 3 808,26

21/02/20

23

 5 1751 6 898,38 9 2654 10 500,23

22/02/20

23

 28 7253 28 260,37 10 6175 24 127,89

23/02/20

23

 10 4183 16 576,06 16 6397 25 492,30

24/02/20

23

 8 2841 11 254,00 7 4920 19 686,54

27/02/20

23

 15 4945 20 465,97 23 9392 38 782,67

28/02/20

23

 8 4758 19 594,73 1 1 4,14

01/03/20

23

 44 24168 98 164,13 21 13428 54 765,96

02/03/20

23

 7 4348 17 573,09 14 11072 44 881,90

03/03/20

23

 23 7139 29 303,10 14 10818 44 581,52

06/03/20

23

 21 9878 40 251,27 2 1475 6 121,24

07/03/20

23

 12 2428 9 765,73 12 5662 22 852,00

08/03/20

23

 2 1128 4 534,58 16 5995 24 413,02

09/03/20

23

 9 4255 17 279,38 3 201 816,08

10/03/20

23

 10 4521 18 071,57 13 4521 18 166,78

 

 

5

13/03/20

23

 34 16201 63 707,19 18 13868 54 802,04

14/03/20

23

 6 1564 6 231,40 7 2823 11 326,53

15/03/20

23

 36 14342 55 968,22 2 1193 4 771,98

16/03/20

23

 10 4527 17 271,68 14 9330 35 837,09

17/03/20

23

 20 7028 27 036,15 8 4286 16 634,39

20/03/20

23

 16 11488 43 332,62 9 4150 15 752,61

21/03/20

23

 11 2546 9 740,92 6 2990 11 482,17

22/03/20

23

 9 2977 11 136,06 9 2552 9 633,49

23/03/20

23

 8 3921 14 731,39 7 3921 14 809,81

24/03/20

23

 24 10272 38 101,11 8 4255 15 745,80

27/03/20

23

 12 6799 24 910,11 16 6056 22 454,56

28/03/20

23

 6 1484 5 376,13 7 2436 8 871,91

29/03/20

23

 9 3281 11 913,31 13 3281 11 987,63

30/03/20

23

 13 4087 14 889,43 13 5524 20 248,00

31/03/20

23

 8 3065 11 223,08 10 4312 15 881,01

03/04/20

23

 15 7643 28 312,88 15 7498 27 951,49

04/04/20

23

 24 6496 24 143,55 14 7819 29 189,11

05/04/20

23

 20 6460 23 595,86 3 262 970,74

06/04/20

23

 17 8018 28 733,95 7 3256 11 763,57

11/04/20

23

 28 10268 36 144,18 14 9962 35 486,34

12/04/20

23

 20 11801 41 041,99 35 19132 67 830,98

13/04/20

23

 9 6657 23 347,56 46 9927 35 256,24

14/04/20

23

 22 14022 49 841,48 24 9548 34 214,40

17/04/20

23

 32 16508 57 069,81 18 8605 29 735,70

18/04/20

23

 19 10543 35 894,38 9 1894 6 428,18

19/04/20

23

 10 5181 17 412,10 17 9124 30 996,51

20/04/20

23

 28 11687 39 801,60 13 7803 26 683,92

21/04/20

23

 32 20929 68 961,26 26 11502 37 717,01

 

 

6

24/04/20

23

 15 5659 18 638,48 18 8012 26 690,54

25/04/20

23

 24 9389 30 924,74 34 23323 78 454,14

26/04/20

23

 15 7436 25 214,29 19 10936 37 742,43

27/04/20

23

 4 2159 7 275,64 11 4796 16 284,58

28/04/20

23

 10 5652 20 244,22 27 19276 68 920,95

02/05/20

23

 13 6404 24 406,41 29 18089 69 631,43

03/05/20

23

 9 5113 19 442,49 7 2138 8 155,14

04/05/20

23

 17 10733 39 931,16 7 5772 21 846,85

05/05/20

23

 4 891 3 429,24 38 20315 76 752,71

08/05/20

23

 13 7077 27 560,88 37 18222 72 501,51

09/05/20

23

 53 20348 77 834,36 12 10650 40 502,59

10/05/20

23

 15 8828 33 994,95 11 7584 29 588,52

11/05/20

23

 8 4823 18 443,92 12 4291 16 553,86

12/05/20

23

 32 16241 60 470,28 22 6861 25 786,59

15/05/20

23

 18 6482 24 186,68 16 9591 36 126,52

16/05/20

23

 23 7522 28 558,70 12 7835 29 961,04

17/05/20

23

 23 7000 26 535,74 20 8608 33 080,54

18/05/20

23

 13 6298 24 401,35 9 3478 13 589,03

19/05/20

23

 15 6440 25 020,56 16 6438 25 078,78

22/05/20

23

 17 5311 20 611,51 3 511 2 003,09

23/05/20

23

 9 3385 13 053,41 2 401 1 551,87

24/05/20

23

 11 4812 18 494,49 4 2123 8 254,86

25/05/20

23

 15 4246 16 377,33 9 4245 16 438,80

26/05/20

23

 13 3945 15 236,81 15 10505 40 776,31

29/05/20

23

 8 4331 17 172,46 23 10192 40 580,98

30/05/20

23

 13 12258 48 094,75 3 506 1 983,72

31/05/20

23

 27 15820 60 468,79 6 3429 13 222,94

01/06/20

23

 10 5465 20 627,48 12 6720 25 735,79

 

7

02/06/20

23

 9 3288 12 674,85 32 13751 52 932,55

05/06/20

23

 11 9454 37 127,65 34 18682 73 496,67

06/06/20

23

 25 11713 45 975,05 36 17748 69 919,84

07/06/20

23

 70 30373 118 950,69 28 7651 29 759,71

08/06/20

23

 49 17423 67 226,47 16 6059 23 614,41

09/06/20

23

 3 1607 6 106,60 4 7556 28 990,03

12/06/20

23

 5 2895 11 299,76 19 17181 67 437,83

13/06/20

23

 16 7810 30 804,12 35 19812 79 940,83

14/06/20

23

 24 10073 40 490,54 25 9134 37 006,86

15/06/20

23

 16 5692 23 732,91 23 17052 71 431,85

16/06/20

23

 11 3950 16 431,01 13 4667 19 534,15

19/06/20

23

 3 2326 9 703,75 10 4593 19 246,14

20/06/20

23

 7 3290 13 720,65 6 1157 4 824,72

21/06/20

23

 10 3232 13 531,61 8 5123 21 565,32

22/06/20

23

 43 30496 122 394,17 1 1 4,17

23/06/20

23

 30 19207 71 368,99 29 18678 69 876,64

26/06/20

23

 37 16011 58 862,36 6 1321 5 019,80

27/06/20

23

 21 14284 50 753,91 18 8109 29 255,97

28/06/20

23

 5 1866 6 745,52 42 33360 123 913,38

29/06/20

23

 8 7872 29 644,93 17 11091 42 551,62

30/06/20

23

 71 33225 135 088,53 50 26866 122 958,43

 

 

8